Johnson & Johnson shares have experienced a slight decline in recent weeks. With a current price of EUR 144.49 (as of September 28th), the paper has lost 3.50% in value month-on-month. Despite this short-term weakness, the healthcare group remains a solid investment. The dividend yield of 3.12% for 2024 underlines the attractiveness for investors who rely on regular distributions. In addition, the price-earnings ratio (P/E) is in the moderate range at 16.23.
Challenges and outlook
A current challenge for Johnson & Johnson is increasing the settlement payment in the talc litigation to over $8.2 billion. This could put pressure on the share price in the short term. Nevertheless, the company remains well positioned with its wide product range and strong market position. Investors should keep an eye on the upcoming quarterly statement on October 15th, which will provide further insight into the company’s financial performance.
Advertisement
Johnson & Johnson shares: buy or sell?! New Johnson & Johnson analysis from September 29th provides the answer:
The latest Johnson & Johnson figures speak for themselves: there is an urgent need for action for Johnson & Johnson shareholders. Is it worth getting started or should you sell? In the current free analysis from September 29th you will find out what to do now.
Johnson & Johnson: buy or sell? Read more here…
…
